Thank you for your continued interest in Wegovy® as we work toward resolving supply constraints following unprecedented product demand and short-term manufacturing issues. We are on track to make all dose strengths of Wegovy® available in the US towards the end of the year. It will then take a few weeks for product to be broadly available at retail pharmacies across the country.

From the outset, our top priority has been to support current patients who have started treatment with Wegovy® to be able to advance through dose escalation and stay on the maintenance dose. We took several steps as part of that commitment. As such, we ask healthcare providers to continue to hold off initiating new patients on Wegovy® until we confirm more broad availability at the pharmacy level.

Our efforts to restore supply

  • We are on track to make all dose strengths of Wegovy® available in the US towards the end of the year. It will then take a few weeks for product to be broadly available at retail pharmacies across the country.

  • Novo Nordisk is also making plans for additional production capacity to come on-line in 2023.

  • We will ensure that we have all dose strengths of Wegovy® within our inventory before we support new patients being initiated and before we start other promotional efforts, consistent with our commitment to continuity of care.

  • We will continue to monitor the situation closely and will share timely and transparent updates and keep you informed on our progress. 

For patients currently taking Wegovy® please know that some pharmacies may continue to experience normal Wegovy® product delays from time-to-time given supply variability. We encourage patients to contact their local pharmacy in advance to confirm that the pharmacy will be able to fill your prescription. 

We apologize for any delay or disruption in treatment this situation may cause. If you have concerns, please contact your healthcare provider to determine the best approach for your treatment plan, in consideration of this supply situation. 

We take our commitment to patients and the healthcare community very seriously and are doing everything we can to stabilize Wegovy® supply as quickly as possible. We believe the continued strong demand reflects the significant unmet medical need and the importance of this treatment option. 

We appreciate your patience and understand your frustration. If you have concerns, we encourage you to speak to your healthcare provider about the weight management approach that is best for you. 

We are here to help and are ready to answer your questions at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday – and select option 0 for more support.

Please see below for important information, and don’t hesitate to call 1-833-4-WEGOVY (1-833-493-4689) and select option 0 for more support. You are our number one priority and we’re here to help.

Please click here for the Prescribing Information and Medication Guide.

If you are currently on the 0.25 mg, or 0.5 mg or 1 mg dose strength, we do expect there will be a disruption in your treatment, which is an important consideration to discuss with your healthcare provider. 

Currently, we do have adequate stock of the 1.7 and 2.4 mg doses to meet the needs of patients who are already taking or about to start on these two dose strengths, unless there are significant, unforeseen increases in prescriptions. However, some pharmacies may continue to experience normal delays from time-to-time, so we encourage you to contact your local pharmacy in advance to confirm that they will be able to fill your prescription. It is important to note that any decisions around individualized care should always be made together with a healthcare provider.

We sincerely regret and apologize for any delays and disruptions to your care and encourage you to speak to your healthcare provider about your individual situation and other FDA-approved options if you have any concerns. 

We are on track to make all dose strengths of Wegovy® available in the US towards the end of the year. It will then take a few weeks for product to be broadly available at retail pharmacies across the country. Additionally, we are continuing to build inventory and plan to have all dose strengths of Wegovy® available before we support new patients starting treatment and other promotional efforts. We suggest you work with your healthcare provider to determine the best approach for your treatment plan in consideration of this supply situation. Other FDA-approved medications for chronic weight management are available.

 

We've been working hard to restore supply and are making progress. Commercial production at the contract manufacturing organization (CMO) was re-initiated in the second quarter of 2022.  There is expected to be substantially more product in 2023: in the first half of 2023, a second contract manufacturing organization (CMO) is expected to come online and later in the year a second site at the current CMO.

The demand for Wegovy® reinforces the unmet need and has strengthened our promise to not only develop innovative medicines but to partner and advocate to change how obesity is understood, diagnosed and treated.

There are five dose strengths of Wegovy® – the first four increase in a stepwise manner (starting with 0.25 mg, then 0.5 mg, 1 mg and 1.7 mg) until the fifth, maintenance dose (2.4 mg). Earlier this year, we temporarily stopped shipments of Wegovy® 0.25 mg, 0.5 mg and 1 mg dose strengths.

We believe we can meet the needs of patients who are already taking or about to start the 1.7 or 2.4 mg dose strengths and remain confident in our ability to supply them, unless there are significant, unforeseen increases in prescriptions.

For more information about the Wegovy® dosing schedule, click here for the Prescribing Information and Medication Guide.

No. There is nothing to indicate there is a product safety issue. 

Although Wegovy® and Ozempic® both contain semaglutide, they are different products with different indications, dosages, titration schedules, etc. The products are not interchangeable. Other FDA-approved medications for chronic weight management are available. We advise you to speak with your healthcare provider to discuss your treatment options. 

We are aware that there are companies claiming to have availability of Wegovy® or semaglutide. We want consumers and healthcare providers to know and be very clear that Novo Nordisk does not sell Wegovy® (or its active ingredient, semaglutide) for the purposes of compounding with other products. We have not conducted studies to evaluate the safety and efficacy of Wegovy® when compounded with other ingredients. Novo Nordisk is the only company that has FDA approval to market Wegovy® and we supply it in a disposable single-use pen available by prescription only.

No, the way in which we sell and distribute our products has not changed. We distribute our products to wholesalers who supply retail pharmacies nationwide. Which pharmacies or retailers get Wegovy® is outside of our control.

We do want to note that some pharmacies may continue to experience delays from time-to-time, so we encourage you to contact your local pharmacy in advance to confirm that they will be able to fill your prescription.

We also want to acknowledge the growing trend of weight-management telehealth providers, many of whom are advertising Wegovy®. Novo Nordisk is not directly supplying Wegovy® to any telehealth providers. 

 

Please call 1-833-4-WEGOVY (1-833-493-4689) and select option 0.

Let us know! Please rate your experience with this page. *

{{crossValidationError['Was this page helpful'].crossValidationErrorMessage}}

If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. We will be reviewing that information on an ongoing basis and making periodic updates to this page. Please know that we take our responsibility to support you in this journey very seriously and are addressing this issue as a top priority. Thank you for your patience as we work to resolve this issue – which we will.